Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effects of Tirzepatide on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Obese Patients: Insights from a Multicenter Real-World Study

  • By

  • Martina Galasso

  • Ludovica Verde

  • Renato Patrone

  • Giovanni Ragozzino

  • Giuseppe Annunziata

  • Annamaria Colao

  • Luigi Barrea

  • Giovanna Muscogiuri

  • July 6, 2026

Share

Original Source(s)

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

  • by Martina Galasso, Ludovica Verde, Renato Patrone, Giovanni Ragozzino, Giuseppe Annunziata, Annamaria Colao, Luigi Barrea, Giovanna Muscogiuri

  • July 6, 2026

Related Content

Association between metabolic risk factors and hepatocellular carcinoma: a systematic review and meta-analysis of cohort studies

Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health

Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study